GVHD is the main complication occurring after allo-SCT and steroids are the first-line therapy for acute GVHD (aGVHD), with a 35% complete response rate. 1 Use of monoclonal antibodies against TNF-a is one of the possible therapeutic approaches for steroid-refractory cases and recent studies in adults have shown that etanercept is effective. [1] [2] [3] However, large studies in patients treated with anti-TNF-a for severe autoimmune diseases showed that infections, especially tuberculosis, invasive mycoses and bacteremias, are important complications, even if patients receiving etanercept show the lowest incidence of these severe adverse events. 4, 5 Data in adults treated with etanercept for steroid-refractory aGVHD indicated an incidence of complicating bacterial and fungal infections ranging from 14 to 80%. 2, 6, 7 Currently, there are no studies available on the occurrence of severe infections in children receiving etanercept for steroid-refractory aGVHD.
In September 2007, we started a program of etanercept administration for treating steroid-refractory aGVHD in children receiving allogeneic SCT at G Gaslini Children's Hospital, Genova,Italy. Etanercept was administered s.c. twice weekly for 8 weeks (16 doses) at a dose of 0.4 mg/kg (maximum dose, 25 mg). During etanercept treatment, methylprednisolone was maintained at a dose of 2 mg/kg/ day for at least 1 week after the initial response to therapy and the dose was then tapered as appropriate. The protocol was approved by the Hospital Ethics Committee. All parents signed the informed consent as per the Declaration of Helsinki. The presence of an uncontrolled infection or personal or familial history of tuberculosis was an exclusion criterion. The management protocol for infectious complications following SCT included (1) fluconazole prophylaxis until day þ 100 from SCT; (2) low dosage of trimethoprimsulfamethoxazole for Pneumocystis jirovecii prophylaxis; and (3) high dosage of acyclovir for Herpes simplex virus, VZV and CMV prophylaxis. In case of febrile complications, blood cultures were performed and empirical antibacterial therapy was started; sequential evaluation of galactomannan and computed tomography (CT) scans were performed for early detection of invasive fungal diseases (IFDs), and cultures for bacteria and fungi were performed at any suspected site of infection. The incidence of infectious complications was one of the variables that had to be monitored to evaluate the safety of the experimental program.
In August 2009, during study monitoring, we recorded a high incidence of severe infectious complications in the cohort of 11 patients at the time of enrollment and therefore we performed an interim analysis. The patients enrolled were aged 2.9-13.9 years (median 9.3); four had been transplanted for Fanconi anemia, two for inborn defects of metabolism and one each for stage 4 neuroblastoma, non-Hodgkin's lymphoma, severe aplastic anemia, juvenile myelomonocytic leukemia and acute myeloid leukemia. An SCT from a matched related donor was performed in five cases, while six received SCTs from an alternative donor. The conditioning regimens included myeloablative regimens in four patients and non-myeloablative or reduced intensity regimens in seven others. Anti-thymocyte globulin (thymoglobulin, IMTIX, Sangstat, Lyon, France) had been administered as GVHD prophylaxis to six patients. aGVHD developed at a median of 18 days after SCT (range 10-49 days) and patients had received 2 mg/kg/day methylprednisolone as first-line therapy. Two patients had grade 2 aGVHD, four had grade 3 aGVHD and five children had grade 4 aGVHD.
At least one episode of bacteremia or IFD was observed in 9 (82%) patients, with four developing at least one episode of both types of complications. Bacteremia accounted for six episodes (three due to Gram-positive bacteria and three due to Gram-negative bacteria), while IFD accounted for seven episodes. IFDs were classified according to internationally approved criteria, 8 in proven infections in four cases (two cases of isolated fungemia due to Candida parapsilosis, one case of disseminated aspergillosis and one case of rhinosinusitis due to Absidia corymbifera); probable IFD in two cases (pulmonary lesions in CT scan and positive galactomannan Ag in one case, and sinusal infiltrations and lung nodules in CT scan with concomitant isolation of an Aspergillus niger from nasal swab in the other); and possible IFD in one case defined by the presence of lung nodules in CT scan in the absence of any mycological or microbiological support. IFD was the cause of death in two patients, after 36 and 102 days from the beginning of etanercept therapy, respectively, whereas no patient died of bacteremia. The duration of follow-up after the first dose of etanercept ranged from 36 to 615 days (median 403), for a total of 3920 patient-days at risk. Therefore, the rates of infectious complications per 1000 patient-days at risk were 1.53 for bacteremias and 1.78 for IFD. Table 1 shows the data on the epidemiology of infectious complications observed. The time elapsed between the first administration of etanercept and the first bacteremic episode ranged from 43 to 299 days, while that before the first IFD ranged from 18 to 85 days. After administering etanercept, 6 (54%) patients showed CR of aGVHD, 1 (9%) had partial response, whereas the treatment failed in 2 patients (both affected by hepatic aGVHD).
These data indicate that severe infectious complications occurred in a high proportion (82%) of patients receiving etanercept, but were reasonably consistent with other reports in adults. [1] [2] [3] However, our data showed that these infections occurred during a quite short period of followup, thus yielding a high rate per 1000 person-days at risk. These values were higher than those we observed in a cohort of allo-SCT recipients when this drug was not administered 9 (Table 1) , which represented our patients' expected event rate at the time of beginning the etanercept therapeutic program. We agree that the reference group included all the patients receiving allo-SCT and therefore was not completely comparable to the present study group regarding severity of GVHD and immunosuppressive therapies. However, as, in our reference study, 9 we did not find any difference in the epidemiology of bacteremias or IFDs according to the type of immunosuppression, but only according to the type of SCT donor, we believe that the data from this reference group could be sufficiently representative of the epidemiology of severe infections after SCT, especially for the purpose of the present report, which was to give a warning on the epidemiology of infectious complications during etanercept therapy for steroid-resistant aGVHD.
In conclusion, data from our prospective cohort study on the use of etanercept for steroid-resistant aGVHD showed that the incidence of severe bacterial and fungal infections was from 2 to more than 10 times higher than that observed when this treatment was not used. However, this high incidence of severe infections should be weighed against the poor prognosis of patients affected by refractory aGVHD, which has a mortality rate of approximately 70%, 7 as we obtained a favorable response of approximately 60% after etanercept therapy. 
